The US Food & Drug Administration (FDA) has advised GTx to stop development of GTx-758 (also known as Capesaris), its oral drug intended for the treatment of men with advanced prostate cancer, after it became apparent that there was an increase in risk for blood clots in men taking active drug compared to those being treated with a placebo. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: blood clots, Capesaris, complications, GTx-758, risk | Leave a comment »
GTx, Inc. has announced the initiation of a randomized Phase IIb trial of their selective estrogen receptor α agonist Capsesaris™ (previously known as GTx-758) versus leuprolide acetate (Lupron Depot®) as first-line androgen deprivation therapy for progressive and advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Management | Tagged: androgen deprivation, Capesaris, estrogen receptor agonist, GTx-758 | Leave a comment »
GTx, Inc. has announced this morning that the company is planning a Phase IIb clinical trial of its oral, selective estrogen receptor agonist (GTx-758, also known as Capesaris™) as a potential first-line treatment for advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Uncategorized | Tagged: androgen deprivation therapy, Capesaris, GTx-758 | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 